NASDAQ:GNCA - Genocea Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.94 -0.04 (-4.08 %)
(As of 05/22/2018 06:54 AM ET)
Previous Close$0.9792
Today's Range$0.9201 - $1.00
52-Week Range$0.79 - $6.78
Volume383,916 shs
Average Volume765,082 shs
Market Capitalization$80.39 million
P/E Ratio-0.47
Dividend YieldN/A
Beta1.22

About Genocea Biosciences (NASDAQ:GNCA)

Genocea Biosciences logoGenocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform AnTigen Lead Acquisition System to design immunotherapies and vaccines that act through T cell immune responses. Its lead product candidate is GEN-003, an investigational immunotherapy that is in Phase III trial for the treatment of genital herpes infections. The company is also develops GEN-009, which is in pre-clinical stage to treat neoantigen cancer; GEN-010 that is in pre-clinical stage for the treatment of patients in second generation neoantigen cancer; GEN-007, which is in research stage to Epstein-Barr virus; and GEN-006 that is in research stage for the treatment of immune-oncology-tumor-associated antigen cancer. It license agreement with University of California and Harvard University; and collaboration agreement with Novavax, Inc. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Receive GNCA News and Ratings via Email

Sign-up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GNCA
CUSIPN/A
Phone617-876-8191

Debt

Debt-to-Equity Ratio1.00
Current Ratio8.06
Quick Ratio8.06

Price-To-Earnings

Trailing P/E Ratio-0.47
Forward P/E Ratio-1.68
P/E GrowthN/A

Sales & Book Value

Annual Sales$230,000.00
Price / Sales335.54
Cash FlowN/A
Price / CashN/A
Book Value($0.07) per share
Price / Book-13.43

Profitability

EPS (Most Recent Fiscal Year)($1.98)
Net Income$-56,710,000.00
Net MarginsN/A
Return on Equity-698.17%
Return on Assets-148.19%

Miscellaneous

Employees52
Outstanding Shares82,100,000

Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions

What is Genocea Biosciences' stock symbol?

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences (NASDAQ:GNCA) issued its earnings results on Thursday, May, 10th. The biotechnology company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14). View Genocea Biosciences' Earnings History.

When is Genocea Biosciences' next earnings date?

Genocea Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Genocea Biosciences.

What price target have analysts set for GNCA?

7 analysts have issued 12-month target prices for Genocea Biosciences' stock. Their forecasts range from $2.50 to $10.00. On average, they anticipate Genocea Biosciences' stock price to reach $4.7857 in the next year. View Analyst Ratings for Genocea Biosciences.

What are Wall Street analysts saying about Genocea Biosciences stock?

Here are some recent quotes from research analysts about Genocea Biosciences stock:
  • 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (4/18/2018)
  • 2. Cantor Fitzgerald analysts commented, "GNCA shares could experience some weakness on the news of the departure of the CFO, Jonathan Poole, who resigned effective 3/23, to pursue other opportunities." (3/11/2018)

Who are some of Genocea Biosciences' key competitors?

Who are Genocea Biosciences' key executives?

Genocea Biosciences' management team includes the folowing people:
  • Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 49)
  • Dr. George R. Siber M.D., Ph.D., Chairman of Scientific Advisory Board & Exec. Director (Age 73)
  • Dr. Darren Higgins Ph.D., Scientific Co-Founder and Member of Scientific Advisory Board
  • Dr. Jessica Baker Flechtner, Chief Scientific Officer (Age 46)
  • Mr. Eric S. Hoffman, Chief Bus. Officer (Age 48)

Has Genocea Biosciences been receiving favorable news coverage?

News coverage about GNCA stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Genocea Biosciences earned a coverage optimism score of 0.13 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 46.41 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Genocea Biosciences' major shareholders?

Genocea Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (30.45%), BVF Inc. IL (6.09%), BlackRock Inc. (4.82%), Northern Trust Corp (0.97%), GSA Capital Partners LLP (0.29%) and Birchview Capital LP (0.23%). Company insiders that own Genocea Biosciences stock include Eric S Hoffman, Jonathan Poole and William D Clark. View Institutional Ownership Trends for Genocea Biosciences.

Which major investors are buying Genocea Biosciences stock?

GNCA stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC, BVF Inc. IL, BlackRock Inc., Northern Trust Corp, GSA Capital Partners LLP, Schwab Charles Investment Management Inc., Birchview Capital LP and California State Teachers Retirement System. Company insiders that have bought Genocea Biosciences stock in the last two years include Eric S Hoffman, Jonathan Poole and William D Clark. View Insider Buying and Selling for Genocea Biosciences.

How do I buy shares of Genocea Biosciences?

Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genocea Biosciences' stock price today?

One share of GNCA stock can currently be purchased for approximately $0.94.

How big of a company is Genocea Biosciences?

Genocea Biosciences has a market capitalization of $80.39 million and generates $230,000.00 in revenue each year. The biotechnology company earns $-56,710,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. Genocea Biosciences employs 52 workers across the globe.

How can I contact Genocea Biosciences?

Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]


MarketBeat Community Rating for Genocea Biosciences (GNCA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  143 (Vote Underperform)
Total Votes:  368
MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe GNCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNCA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Genocea Biosciences (NASDAQ:GNCA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Genocea Biosciences in the last 12 months. Their average twelve-month price target is $4.7857, suggesting that the stock has a possible upside of 409.12%. The high price target for GNCA is $10.00 and the low price target for GNCA is $2.50. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.802.60
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.7857$4.7857$4.70$7.3750
Price Target Upside: 409.12% upside285.94% upside405.38% upside535.78% upside

Genocea Biosciences (NASDAQ:GNCA) Consensus Price Target History

Price Target History for Genocea Biosciences (NASDAQ:GNCA)

Genocea Biosciences (NASDAQ:GNCA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018HC WainwrightSet Price TargetBuy$5.00LowView Rating Details
3/11/2018Cantor FitzgeraldSet Price TargetBuy$5.00LowView Rating Details
2/12/2018Robert W. BairdInitiated CoverageOutperform$3.00HighView Rating Details
2/6/2018Needham & Company LLCUpgradeHold ➝ Buy$3.00HighView Rating Details
11/2/2017Piper Jaffray CompaniesReiterated RatingOverweight$5.00N/AView Rating Details
9/26/2017CowenReiterated RatingBuy$10.00HighView Rating Details
9/25/2017Stifel NicolausDowngradeBuy ➝ Hold$15.00 ➝ $2.50HighView Rating Details
1/23/2017FBR & CoReiterated RatingOutperformN/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Genocea Biosciences (NASDAQ:GNCA) Earnings History and Estimates Chart

Earnings by Quarter for Genocea Biosciences (NASDAQ:GNCA)

Genocea Biosciences (NASDAQ:GNCA) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.56 EPS
Next Year EPS Consensus Estimate: $-0.64 EPS

Genocea Biosciences (NASDAQ GNCA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($0.13)N/AView Earnings Details
5/10/2018Q1 2018($0.14)($0.14)ViewN/AView Earnings Details
2/16/2018Q4 2017($0.40)($0.37)ViewN/AView Earnings Details
11/2/2017Q3 2017($0.51)($0.59)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.46)($0.54)ViewN/AView Earnings Details
5/4/20173/31/2017($0.54)($0.48)ViewListenView Earnings Details
2/16/2017Q416($0.45)($0.56)ViewN/AView Earnings Details
11/3/2016Q316($0.44)($0.45)ViewN/AView Earnings Details
8/4/2016Q216($0.44)($0.39)ViewN/AView Earnings Details
5/5/2016Q116($0.42)($0.35)$0.24 millionViewN/AView Earnings Details
2/11/2016Q415($0.40)($0.37)$0.22 millionViewListenView Earnings Details
11/5/2015Q315($0.43)($0.37)$0.21 millionViewListenView Earnings Details
8/6/2015Q215($0.51)($0.43)$0.12 millionViewN/AView Earnings Details
5/7/2015Q115($0.57)($0.64)$0.12 millionViewListenView Earnings Details
2/12/2015Q414($0.53)($0.66)$0.31 millionViewListenView Earnings Details
11/6/2014Q314($0.43)($0.53)ViewN/AView Earnings Details
8/6/2014Q2($0.42)($0.41)ViewN/AView Earnings Details
5/6/2014Q114($0.60)($0.76)$0.2590 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Genocea Biosciences (NASDAQ:GNCA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Genocea Biosciences (NASDAQ GNCA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.95%
Institutional Ownership Percentage: 65.29%
Insider Trading History for Genocea Biosciences (NASDAQ:GNCA)
Institutional Ownership by Quarter for Genocea Biosciences (NASDAQ:GNCA)

Genocea Biosciences (NASDAQ GNCA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/17/2018William D ClarkCEOBuy25,000$0.80$20,000.0082,931View SEC Filing  
7/24/2017Jonathan PooleCFOSell45,000$6.00$270,000.0084,247View SEC Filing  
11/8/2016Eric S. HoffmanInsiderBuy7,000$3.49$24,430.00View SEC Filing  
11/7/2016Jonathan PooleCFOBuy7,000$3.34$23,380.00View SEC Filing  
11/7/2016William D. ClarkInsiderBuy2,800$3.49$9,772.00View SEC Filing  
5/9/2016Jonathan PooleCFOBuy4,000$3.88$15,520.008,213View SEC Filing  
12/16/2015William D ClarkCEOBuy3,800$6.45$24,510.0043,607View SEC Filing  
9/1/2015Jessica Baker FlechtnerVPSell2,229$11.35$25,299.151,881View SEC Filing  
6/19/2015Polaris Venture Management Co.Major ShareholderSell30,004$13.04$391,252.16View SEC Filing  
6/17/2015Polaris Venture Management Co.Major ShareholderSell10,618$13.01$138,140.18View SEC Filing  
6/16/2015Polaris Venture Management Co.Major ShareholderSell46,000$13.24$609,040.00View SEC Filing  
6/1/2015Jessica Baker FlechtnerVPSell2,229$10.52$23,449.08View SEC Filing  
5/1/2015Jessica Baker FlechtnerVPSell2,229$10.21$22,758.09View SEC Filing  
4/1/2015Jessica Baker FlechtnerVPSell2,283$11.77$26,870.91View SEC Filing  
3/17/2015Stephen J HoffmanDirectorBuy700,000$8.25$5,775,000.00View SEC Filing  
2/2/2015Jessica Baker FlechtnerVPSell4,699$8.50$39,941.50View SEC Filing  
9/12/2014Jessica Baker FlechtnerVPSell6,435$12.00$77,220.00View SEC Filing  
9/11/2014Paul GiannascaVPSell4,071$11.84$48,200.64View SEC Filing  
9/10/2014Paul GiannascaVPSell834$12.35$10,299.90View SEC Filing  
9/9/2014Paul GiannascaVPSell2,455$12.43$30,515.65View SEC Filing  
9/8/2014Paul GiannascaVPSell2,970$12.80$38,016.00View SEC Filing  
8/29/2014Paul GiannascaVPSell6,760$12.50$84,500.00View SEC Filing  
8/14/2014Polaris Venture Management Co.Major ShareholderSell9,660$13.01$125,676.60View SEC Filing  
8/12/2014Polaris Venture Management Co.Major ShareholderSell63,794$13.28$847,184.32View SEC Filing  
2/10/2014Plc GlaxosmithklineInsiderBuy143,773$12.00$1,725,276.00View SEC Filing  
2/10/2014Polaris Venture Management Co.Major ShareholderBuy232,820$12.00$2,793,840.00View SEC Filing  
2/10/2014Stephen J HoffmanDirectorBuy250,931$12.00$3,011,172.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Genocea Biosciences (NASDAQ GNCA) News Headlines

Source:
DateHeadline
Genocea Biosciences (GNCA) Expected to Post Earnings of -$0.14 Per ShareGenocea Biosciences (GNCA) Expected to Post Earnings of -$0.14 Per Share
www.americanbankingnews.com - May 16 at 1:27 PM
Genocea Biosciences (GNCA) Posts Quarterly  Earnings Results, Meets EstimatesGenocea Biosciences (GNCA) Posts Quarterly Earnings Results, Meets Estimates
www.americanbankingnews.com - May 12 at 12:28 AM
Genocea Biosciences (GNCA) CEO Chip Clark on Q1 2018 Results - Earnings Call TranscriptGenocea Biosciences' (GNCA) CEO Chip Clark on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 5:56 PM
Genocea Biosciences: 1Q Earnings SnapshotGenocea Biosciences: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 5:56 PM
Genocea Biosciences (GNCA) Given a $5.00 Price Target at HC WainwrightGenocea Biosciences (GNCA) Given a $5.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 10 at 5:37 PM
Genocea Reports First Quarter 2018 Financial and Operating ResultsGenocea Reports First Quarter 2018 Financial and Operating Results
finance.yahoo.com - May 10 at 8:25 AM
Genocea Biosciences (GNCA) Receives Consensus Recommendation of "Buy" from AnalystsGenocea Biosciences (GNCA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 7 at 9:05 AM
3 Things In Biotech, May 3: Bristol Bows Out Of IDO, And Two Biotechs Look To Investigate Novel Immunotherapies3 Things In Biotech, May 3: Bristol Bows Out Of IDO, And Two Biotechs Look To Investigate Novel Immunotherapies
seekingalpha.com - May 4 at 8:18 AM
Genocea to Host First Quarter 2018 Financial Results Conference Call & Webcast on May 10, 2018 at 9 a.m. ETGenocea to Host First Quarter 2018 Financial Results Conference Call & Webcast on May 10, 2018 at 9 a.m. ET
finance.yahoo.com - May 4 at 8:18 AM
Genocea Biosciences (GNCA) PT Set at $5.00 by HC WainwrightGenocea Biosciences (GNCA) PT Set at $5.00 by HC Wainwright
www.americanbankingnews.com - April 30 at 2:32 PM
Genocea Files Investigational New Drug Application for Neoantigen Cancer Vaccine Candidate GEN-009Genocea Files Investigational New Drug Application for Neoantigen Cancer Vaccine Candidate GEN-009
finance.yahoo.com - April 30 at 8:24 AM
-$0.14 Earnings Per Share Expected for Genocea Biosciences (GNCA) This Quarter-$0.14 Earnings Per Share Expected for Genocea Biosciences (GNCA) This Quarter
www.americanbankingnews.com - April 28 at 11:06 PM
Genocea Biosciences (GNCA) Set to Announce Quarterly Earnings on WednesdayGenocea Biosciences (GNCA) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 25 at 3:52 AM
Genocea Biosciences (GNCA) Highlights Data from ATLAS Platform at 2018 AACR MeetingsGenocea Biosciences (GNCA) Highlights Data from ATLAS Platform at 2018 AACR Meetings
www.streetinsider.com - April 19 at 8:16 AM
Genocea Presents Data at AACR Annual Meeting Further Highlighting Advantages of ATLAS Platform in Identification of Neoantigens over in silico MethodsGenocea Presents Data at AACR Annual Meeting Further Highlighting Advantages of ATLAS Platform in Identification of Neoantigens over in silico Methods
finance.yahoo.com - April 18 at 5:45 PM
Genocea Biosciences (GNCA) Raised to "Buy" at Zacks Investment ResearchGenocea Biosciences (GNCA) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 18 at 10:41 AM
Head-To-Head Review: Genocea Biosciences (GNCA) & Biogen (BIIB)Head-To-Head Review: Genocea Biosciences (GNCA) & Biogen (BIIB)
www.americanbankingnews.com - April 18 at 1:30 AM
Genocea Biosciences (GNCA) Upgraded to "Hold" by ValuEngineGenocea Biosciences (GNCA) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - April 16 at 7:34 PM
ValuEngine Downgrades Genocea Biosciences (GNCA) to SellValuEngine Downgrades Genocea Biosciences (GNCA) to Sell
www.americanbankingnews.com - April 14 at 1:59 PM
Short Interest in Genocea Biosciences Inc (GNCA) Increases By 72.8%Short Interest in Genocea Biosciences Inc (GNCA) Increases By 72.8%
www.americanbankingnews.com - April 13 at 2:10 AM
Genocea Biosciences Inc (GNCA) Receives Consensus Rating of "Buy" from AnalystsGenocea Biosciences Inc (GNCA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 12 at 8:49 AM
-$0.14 EPS Expected for Genocea Biosciences Inc (GNCA) This Quarter-$0.14 EPS Expected for Genocea Biosciences Inc (GNCA) This Quarter
www.americanbankingnews.com - April 12 at 1:13 AM
Contrasting Genocea Biosciences (GNCA) and TrovaGene (TROV)Contrasting Genocea Biosciences (GNCA) and TrovaGene (TROV)
www.americanbankingnews.com - April 8 at 10:15 AM
Genocea Biosciences (GNCA) Downgraded by Zacks Investment ResearchGenocea Biosciences (GNCA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 31 at 11:09 AM
Genocea Biosciences Inc (GNCA) Short Interest Up 66.5% in MarchGenocea Biosciences Inc (GNCA) Short Interest Up 66.5% in March
www.americanbankingnews.com - March 30 at 3:38 AM
Genocea Biosciences Inc (GNCA) Given Average Rating of "Buy" by BrokeragesGenocea Biosciences Inc (GNCA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 18 at 8:54 AM
Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences ... - NasdaqGenocea Appoints Narinder Singh as SVP Pharmaceutical Sciences ... - Nasdaq
www.nasdaq.com - March 13 at 8:26 AM
Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences & Manufacturing - GlobeNewswire (press release)Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences & Manufacturing - GlobeNewswire (press release)
www.globenewswire.com - March 13 at 8:26 AM
Genocea Biosciences Inc (GNCA) Short Interest UpdateGenocea Biosciences Inc (GNCA) Short Interest Update
www.americanbankingnews.com - March 13 at 1:08 AM
Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences & ManufacturingGenocea Appoints Narinder Singh as SVP Pharmaceutical Sciences & Manufacturing
finance.yahoo.com - March 12 at 6:39 PM
Cantor Fitzgerald Reiterates Buy Rating for Genocea Biosciences (GNCA)Cantor Fitzgerald Reiterates Buy Rating for Genocea Biosciences (GNCA)
www.americanbankingnews.com - March 11 at 8:18 PM
Genocea Biosciences Inc Forecasted to Post FY2018 Earnings of ($0.59) Per Share (GNCA)Genocea Biosciences Inc Forecasted to Post FY2018 Earnings of ($0.59) Per Share (GNCA)
www.americanbankingnews.com - March 9 at 10:35 AM
HC Wainwright Begins Coverage on Genocea Biosciences (GNCA)HC Wainwright Begins Coverage on Genocea Biosciences (GNCA)
www.americanbankingnews.com - March 8 at 11:40 PM
HC Wainwright Takes Bullish Stance On Two Cancer-Focused Pharma CompaniesHC Wainwright Takes Bullish Stance On Two Cancer-Focused Pharma Companies
finance.yahoo.com - March 8 at 6:43 PM
Cantor Fitzgerald Initiates Coverage on Genocea Biosciences (GNCA)Cantor Fitzgerald Initiates Coverage on Genocea Biosciences (GNCA)
www.americanbankingnews.com - March 5 at 7:20 PM
Genocea to Present at Two March Investor Conferences - GlobeNewswire (press release)Genocea to Present at Two March Investor Conferences - GlobeNewswire (press release)
globenewswire.com - March 5 at 8:17 AM
Genocea to Present at Two March Investor ConferencesGenocea to Present at Two March Investor Conferences
finance.yahoo.com - March 5 at 8:17 AM
Genocea Biosciences Inc (NASDAQ:GNCA): Does The -14.40% Earnings Decline Make It An Underperformer?Genocea Biosciences Inc (NASDAQ:GNCA): Does The -14.40% Earnings Decline Make It An Underperformer?
finance.yahoo.com - February 24 at 8:15 AM
Genocea Biosciences Inc (GNCA) Given Consensus Recommendation of "Hold" by BrokeragesGenocea Biosciences Inc (GNCA) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 21 at 7:36 AM
Genocea Biosciences Inc (GNCA) Expected to Announce Earnings of -$0.20 Per ShareGenocea Biosciences Inc (GNCA) Expected to Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - February 20 at 3:08 AM
Genocea Biosciences (GNCA) Releases Quarterly  Earnings Results, Beats Expectations By $0.03 EPSGenocea Biosciences (GNCA) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - February 16 at 11:40 AM
Genocea Biosciences, Inc. to Host Earnings CallGenocea Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - February 15 at 9:29 AM
Genocea Reports Fourth Quarter and Full-Year 2017 Financial ResultsGenocea Reports Fourth Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - February 15 at 9:29 AM
Genocea Biosciences (GNCA) Appoints Ali Behbahani M.D. to BoardGenocea Biosciences (GNCA) Appoints Ali Behbahani M.D. to Board
www.streetinsider.com - February 13 at 9:58 AM
NEA Partner Ali Behbahani, M.D. Joins Genocea Biosciences’ Board of DirectorsNEA Partner Ali Behbahani, M.D. Joins Genocea Biosciences’ Board of Directors
finance.yahoo.com - February 13 at 9:58 AM
Genocea Biosciences (GNCA) Earns Outperform Rating from Analysts at Robert W. BairdGenocea Biosciences (GNCA) Earns Outperform Rating from Analysts at Robert W. Baird
www.americanbankingnews.com - February 12 at 9:00 PM
Short Interest in Genocea Biosciences Inc (GNCA) Grows By 73.9%Short Interest in Genocea Biosciences Inc (GNCA) Grows By 73.9%
www.americanbankingnews.com - February 9 at 4:58 PM
Genocea to Host Fourth Quarter and Year End 2017 Financial Results Conference Call & Webcast on February 15, 2018 at 9 a.m. ETGenocea to Host Fourth Quarter and Year End 2017 Financial Results Conference Call & Webcast on February 15, 2018 at 9 a.m. ET
finance.yahoo.com - February 8 at 8:11 AM
Genocea Biosciences (GNCA) Scheduled to Post Quarterly Earnings on WednesdayGenocea Biosciences (GNCA) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 7 at 2:14 AM
Genocea Biosciences (GNCA) Upgraded by Needham & Company LLC to "Buy"Genocea Biosciences (GNCA) Upgraded by Needham & Company LLC to "Buy"
www.americanbankingnews.com - February 6 at 11:30 PM

SEC Filings

Genocea Biosciences (NASDAQ:GNCA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Genocea Biosciences (NASDAQ:GNCA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Genocea Biosciences (NASDAQ GNCA) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.